ErSO-TFPy

Synonyms: TEQ103; Sera2
ErSO-TFPy (TEQ103) 是一种对 ERα+ 乳腺癌细胞具有纳摩尔级低浓度细胞毒活性的 ERα+ 肿瘤细胞抑制剂,可通过激活钠通道 TRPM4 导致细胞内钙、钠离子失衡,失调 ERα+ 肿瘤细胞内的钙稳态,触发预适应性未折叠蛋白反应,并诱导不依赖免疫细胞的快速坏死性细胞死亡,可用于雌激素受体 α 阳性乳腺癌的相关研究。
产品编号: MS-L08491 纯度: 99.33% CAS No.: 3035547-78-2 分子式: C19H13F7N2O2 分子量: 434.31
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

ErSO-TFPy (TEQ103) 是一种对 ERα+ 乳腺癌细胞具有纳摩尔级低浓度细胞毒活性的 ERα+ 肿瘤细胞抑制剂,可通过激活钠通道 TRPM4 导致细胞内钙、钠离子失衡,失调 ERα+ 肿瘤细胞内的钙稳态,触发预适应性未折叠蛋白反应,并诱导不依赖免疫细胞的快速坏死性细胞死亡,可用于雌激素受体 α 阳性乳腺癌的相关研究。

生物实验数据

生物活性 ErSO-TFPy (TEQ103) is an ERα+ tumor cell inhibitor with nanomolar-level cytotoxic activity against ERα+ breast cancer cells that activates the sodium channel TRPM4 to cause intracellular calcium and sodium ion imbalance, dysregulates calcium homeostasis in ERα+ tumor cells, triggers a pre-adaptive unfolded protein response, and induces rapid immunocyte-independent necrotic cell death, and can be used for research related to estrogen receptor α-positive breast cancer.
IC50 & Target

TRPM4

 

体外研究
(In Vitro)

ErSO-TFPy (72 h) 可强效抑制 ERα 阳性人乳腺癌细胞系的活力,孵育 72 小时后的 IC50 值约为 5-25 nM,而对 ERα 阴性人乳腺癌细胞系的活性极低。
ErSO-TFPy (150-450 nM; 6 h) 可在孵育 6 小时后,于 150 nM 和 450 nM 浓度下激活 MCF-7 人乳腺癌细胞中的预期未折叠蛋白反应,这一点可通过 EIF2α 磷酸化水平升高、AMPK 磷酸化水平升高以及 ATF6 的剪切得到验证。
ErSO-TFPy (≥0.01 μM;72 h) 可在人乳腺癌 MCF-7 细胞中诱导强烈的 TRPM4 依赖性细胞死亡,在孵育 72 小时且浓度≥0.01 μM 的条件下细胞死亡率约为 80%,而 MCF-7 TRPM4 KO 细胞对 ErSO-TFPy 诱导的细胞死亡的敏感性降低了约 1000 倍。
ErSO-TFPy (1 μM; 2 h) 可在孵育 2 小时后,以 1 μM 的浓度在人乳腺癌亲本细胞 MCF-7 中诱导显著的 TRPM4 依赖性细胞肿胀,而 TRPM4 敲除的 MCF-7 细胞未出现可检测到的细胞肿胀。
ErSO-TFPy (24-120 h) 可强效抑制 MCF-7、MCF-7Y537S 突变体及 MCF-7D538G 突变体人乳腺癌细胞的活力;在 10% FBS 以及 10% CD-FBS + 1 nM E2 两种培养基条件下孵育 24 h 和 120 h 后,其 IC50 值均为个位数纳摩尔级别。

Western Blot Analysis

Cell Line: MCF-7 human breast cancer cells
Concentration: 150 nM, 450 nM
Incubation Time: 6 h
Result: Induced activation of anticipatory unfolded protein response markers, including phosphorylation of EIF2α, phosphorylation of AMPK, and cleavage of ATF6.

Cell Viability Assay

Cell Line: MCF-7 Parental and MCF-7 TRPM4 KO human breast cancer cells
Concentration: ≥0.01 μM (MCF-7 Parental; 72 h); 100 μM (MCF-7 TRPM4 KO; 168 h)
Incubation Time: 24 h, 72 h, 168 h
Result: Induced ~80% cell death in MCF-7 Parental cells at concentrations ≥0.01 μM after 72 h. Reduced cell death induction by ~1000-fold in MCF-7 TRPM4 KO cells, with minimal cell death observed even at 100 μM after 168 h.

Cell Viability Assay

Cell Line: MCF-7, MCF-7 Y537S mutant, and MCF-7 D538G mutant human breast cancer cells
Concentration: 4-8 nM (24 h); 4-8 nM (120 h)
Incubation Time: 24 h, 120 h
Result: Exhibited single-digit nanomolar IC50 values in 10% FBS media: 8 nM (24 h), 5 nM (120 h) in MCF-7 cells; 5 nM (24 h), 4 nM (120 h) in MCF-7 Y537S cells; 6 nM (24 h), 6 nM (120 h) in MCF-7 D538G cells. Exhibited single-digit nanomolar IC50 values in 10% CD-FBS + 1 nM E2 media: 7nM (24 h), 6 nM (120 h) in MCF-7 cells; 4 ± 1 nM (24 h), 6 nM (120 h) in MCF-7 Y537S cells; 5 nM (24 h), 8 nM (120 h) in MCF-7 D538G cells.

Cell Cytotoxicity Assay

Cell Line: MCF-7 human breast cancer cells
Concentration: 50 nM
Incubation Time: 24 h, 120 h
Result: Induced ~80% cell death at 50 nM after 24 h incubation. Induced ~80% cell death at 50 nM after 120 h incubation.
体内研究
(In Vivo)

ErSO-TFPy (TEQ103) (1-150 mg/kg total dose; i.v.) 在荷 MCF-7 肿瘤的无胸腺雌性小鼠中表现出显著且持久的抗肿瘤活性,无论给药方案如何,均实现了 100%的无瘤存活率。
ErSO-TFPy (2-10 mg/kg; i.v.; once weekly; 4 doses) 在 10 mg/kg 剂量下可诱导无胸腺裸鼠体内 MCF-7 ERα+乳腺癌异种移植瘤完全消退,5 mg/kg 剂量下可显著抑制肿瘤生长,2 mg/kg 剂量下无显著抑制作用,且各剂量均未导致显著体重下降。
ErSO-TFPy (20 mg/kg; i.v.; once or twice weekly; 4 doses) 可诱导无胸腺裸鼠中 Fulvestrant (MS-S35194) 耐药的 ST941 ESR1mut 乳腺癌 PDX 肿瘤完全消退。
ErSO-TFPy (2-50 mg/kg; i.v.; single dose) 可在无胸腺裸鼠中诱导 MCF-7 ESR1D538G 乳腺癌异种移植物近乎完全或完全消退,包括体积约 1500 mm3 的大肿瘤;其中 25 mg/kg 或 50 mg/kg 剂量下可实现该效应,5 mg/kg 剂量下有显著抑制作用,2 mg/kg 剂量下则无显著抑制作用。
ErSO-TFPy (50 mg/kg; i.v.; single dose) 可在无胸腺裸鼠中显著诱导 BT-474 ERα+/HER2+ 乳腺癌异种移植物 (包括已长成的大型肿瘤) 发生消退。
ErSO-TFPy (50 mg/kg; i.v.; single dose) 可诱导 MCF-7 ESR1D538G 乳腺癌异种移植物发生快速坏死性细胞死亡,在给药后 3 至 5 天可观察到超过 90%的肿瘤坏死,且经评估的免疫细胞群体在肿瘤细胞死亡中无显著早期参与。

Animal Model: Athymic (female; bearing ~500 mm3 subcutaneous MCF-7 tumors)
Dosage: 1 mg/kg, 2 mg/kg, 4 mg/kg, 15 mg/kg, 30 mg/kg; 1 mg/kg, 5 mg/kg, 20 mg/kg, 75 mg/kg, 150 mg/kg (intermittent schedule, day 1 and day 10)
Administration: i.v.; daily for 10 days (daily schedule); i.v.; single doses on day 1 and day 10 (intermittent schedule)
Result: Achieved 2/9 tumor-free survivors and a 44-day tumor growth delay in relapsing mice with 2 mg/kg daily schedule. Achieved 4/9 tumor-free survivors and a 56-day tumor growth delay in relapsing mice with 5 mg/kg intermittent schedule. Induced 100% tumor-free survivors with complete regressions lasting 121 days post-tumor induction at total dosages ≥40 mg/kg across both schedules. Caused no body weight loss in all studied dose ranges.
Animal Model: Athymic nude mice (female, with exogenous estradiol pellet)
Dosage: 2 mg/kg; 5 mg/kg; 10 mg/kg
Administration: i.v.; once weekly; 4 doses
Result: Showed no significant tumor growth inhibition relative to vehicle at 2 mg/kg.\nInduced significant tumor growth inhibition at 5 mg/kg.\nInduced complete tumor regression at 10 mg/kg.\nCaused no significant weight loss in any treatment group.
Animal Model: Athymic nude mice
Dosage: 20 mg/kg
Administration: i.v.; once weekly; 4 doses; i.v.; twice weekly; 4 doses
Result: Induced complete tumor regression in all 8 treated mice with both administration schedules.\nCaused significant reduction in tumor volume relative to vehicle with both administration schedules.
Animal Model: Athymic nude mice (female)
Dosage: 2 mg/kg; 5 mg/kg; 25 mg/kg; 50 mg/kg
Administration: i.v.; single dose (day 0); i.v.; single dose (day 53)
Result: Showed no significant tumor growth inhibition at 2 mg/kg.\nInduced significant tumor growth inhibition at 5 mg/kg.\nInduced >80% tumor volume reduction within 14 days at 25 mg/kg and 50 mg/kg.\nResulted in 5/5 mice having no measurable tumors by day 66 at 50 mg/kg.\nInduced >90% tumor regression in ~1500 mm3 tumors treated with 50 mg/kg at day 53.
Animal Model: Athymic nude mice (implanted with 0.5 mg 90-day release estrogen pellet)
Dosage: 50 mg/kg
Administration: i.v.; single dose (day 0); i.v.; single dose (day 28)
Result: Induced >80% tumor volume reduction within 14 days, with tumors continuing to regress through day 35, when treated at day 0.\nCaused significant tumor regression in large tumors treated at day 28.
Animal Model: Athymic nude mice (female)
Dosage: 50 mg/kg
Administration: i.v.; single dose
Result: Induced degenerative state in tumors by day 1 post-treatment.\nCaused >90% of tumor tissue to be necrotic by days 3 and 5 post-treatment.\nReduced Ki67+ proliferative cells and cleaved caspase-3+ apoptotic cells significantly relative to vehicle in day 1 tumor tissue.\nCaused no significant difference in Ly6G+ neutrophils, CD11c+ dendritic cells, or F4/80+ macrophages in viable tumor regions relative to vehicle.
性状 固体
颜色 White to off-white

化学信息

分子量 434.31
分子式 C19H13F7N2O2
CAS No. 3035547-78-2
别名 TEQ103; Sera2

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (230.25 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.3025 mL11.5125 mL23.0250 mL57.5626 mL
5 mM0.4605 mL2.3025 mL4.6050 mL11.5125 mL
10 mM0.2303 mL1.1513 mL2.3025 mL5.7563 mL
15 mM0.1535 mL0.7675 mL1.5350 mL3.8375 mL
20 mM0.1151 mL0.5756 mL1.1513 mL2.8781 mL
25 mM0.0921 mL0.4605 mL0.9210 mL2.3025 mL
30 mM0.0768 mL0.3838 mL0.7675 mL1.9188 mL
40 mM0.0576 mL0.2878 mL0.5756 mL1.4391 mL
50 mM0.0461 mL0.2303 mL0.4605 mL1.1513 mL
60 mM0.0384 mL0.1919 mL0.3838 mL0.9594 mL
80 mM0.0288 mL0.1439 mL0.2878 mL0.7195 mL
100 mM0.0230 mL0.1151 mL0.2303 mL0.5756 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础